Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355928 | 1.00 | LMNA (0.44) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL2470514 | 0.87 | CYP1A2 (0.36) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL1933179 | 0.80 | LMNA (0.47) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL6841476 | 0.78 | — | — | |
| SCHEMBL28496592 | 0.78 | LMNA (0.46) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL18431433 | 0.77 | CYP1A2 (0.32) | CYP1A2 | |
| SCHEMBL18431431 | 0.77 | CYP1A2 (0.32) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL2904704 | 0.77 | LMNA (0.48) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL4365179 | 0.77 | LMNA (0.48) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL44490 | 0.77 | LMNA (0.48) | LMNAKDM4EDUSP3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220142948-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-05-12 | — | — | US | claimed |
| EP-3942023-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | The Broad Institute, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| WO-2020191079-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | THE BROAD INSTITUTE, INC. (US) | 2020-09-24 | — | — | WO | claimed |
| US-20220142948-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-05-12 | — | — | US | disclosed |
| EP-3942023-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | The Broad Institute, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020191079-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | THE BROAD INSTITUTE, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-9556113-B2 | Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment | THE SOUTH DAKOTA BOARD OF REGENTS (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556113-B2 | Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment | THE SOUTH DAKOTA BOARD OF REGENTS (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150315131-A1 | COMBINATION USES OF DICHLOROACETATE AND OXAMATE, AND THEIR PRODRUGS, FOR CANCER TREATMENT | SANFORD RESEARCH | 2015-11-05 | — | — | US | disclosed |
| US-20150315131-A1 | COMBINATION USES OF DICHLOROACETATE AND OXAMATE, AND THEIR PRODRUGS, FOR CANCER TREATMENT | SANFORD RESEARCH | 2015-11-05 | — | — | US | disclosed |
| WO-2011109874-A1 | INHIBITION OF GLUTATHIONE TRANSFERASE ZETA | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2011-09-15 | — | — | WO | disclosed |
| US-5600088-A | POLYMERIC COATING OF PRIMARY OR SECONDARY AMINE AND 3-NITRAZAPENTANE DIISOCYANATE FOR PROPELLANT PARTICLES, TO IMPROVE BONDING STRENGTH WITH BINDERS | AEROJET GENERAL CORPORATION (US) | 1997-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315131-A1 | COMBINATION USES OF DICHLOROACETATE AND OXAMATE, AND THEIR PRODRUGS, FOR CANCER TREATMENT | PDK3, PDK2, PDK4 | LMNA 2839/4885KDM4E 1464/4885DUSP3 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.